COPENHAGEN, June 10 (Reuters) - Danish diabetes drugmaker Novo Nordisk on Saturday presented its findings from the real-world study EU-TREAT at the American Diabetes Association’s 77th Scientific Sessions.
* “Switching to Tresiba provides significant reductions in blood glucose and lower rates of hypoglycaemia in a real-world settings,” Novo Nordisk said in a statement
* People with type 1 diabetes and type 2 diabetes experienced a significant reduction in HbA1c, a measure of long-term blood glucose levels, six months after switching to Tresiba from another basal insulin, primarily rival Sanofi’s Lantus (insulin glargine), and its own insulin Levemir (insulin detemir), in a real-world setting
* Rates of overall hypoglycaemia were also significantly lower at 6 months after switching to Tresiba, it added
* In people with type 1 diabetes, the rate of severe hypoglycaemia was reduced by 85 percent and by 92 percent in people with type 2 diabetes
* “Real-world studies are important to understand how outcomes from clinical trials translate into real-world practice,” said chief science officer Mads Krogsgaard Thomsen
* “Our real-world data presented at ADA reinforce what we have seen in the clinical trial programme” (Reporting by Stine Jacobsen, editing by Teis Jensen)